Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

BOSULIF®Principal Display Panel (bosutinib)

PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label

Pfizer

NDC 0069-0135-01

Bosulif®
(bosutinib) tablets

100 mg*

Do not crush or cut tablet
For Oncology Use Only

120 Tablets

Rx only

PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label

PRINCIPAL DISPLAY PANEL - 500 mg Bottle Label

Pfizer

NDC 0069-0136-01

Bosulif®
(bosutinib) tablets

500 mg*

Do not crush or cut tablet
For Oncology Use Only

30 Tablets

Rx only

PRINCIPAL DISPLAY PANEL - 500 mg Bottle Label

PRINCIPAL DISPLAY PANEL - 400 mg Tablet Bottle Label

Pfizer

NDC 0069-0193-01

Bosulif®
(bosutinib) tablets

400 mg*

Do not crush or cut tablet
For Oncology Use Only

30 Tablets

Rx only

PRINCIPAL DISPLAY PANEL - 400 mg Tablet Bottle Label
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

*9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch